---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-045886"
form_type: "8-K"
ticker: "CGTX"
cik: "0001455365"
company_name: "COGNITION THERAPEUTICS INC"
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T03:51:09.868658+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Cognition Therapeutics: oral zervimesine cuts GA lesion growth 28.6% in Phase 2 trial

## Summary
- Zervimesine-treated patients had 28.6% slower GA lesion growth rate vs placebo in Phase 2 MAGNIFY study.
- At 18 months, mean lesion size was 28.2% smaller for zervimesine group compared to placebo.
- Trial concluded early with ~100 of planned 246 enrolled; company focuses resources on Alzheimer's and DLB programs.
- Dry AMD is third indication where zervimesine showed efficacy signals; oral pill vs current injectable treatments.
- Additional safety, demographic, and visual outcome data still being analyzed; results to be presented at medical meeting.

## SEC filing metadata
- accession: 0001104659-25-045886
- form_type: 8-K
- ticker: CGTX
- cik: 0001455365
- company_name: COGNITION THERAPEUTICS INC
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1455365/000110465925045886/0001104659-25-045886-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1455365/000110465925045886/tm2514313d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-045886
- JSON: https://secwatch.observer/filing/0001104659-25-045886.json
- Plain text: https://secwatch.observer/filing/0001104659-25-045886.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.